TickerFacts.

Company research / SUPN

Supernus Pharmaceuticals, Inc. (SUPN)

Build a valuation ↗↓ Download CSV

SEC name SUPERNUS PHARMACEUTICALS, INC. · CIK 0001356576 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Supernus Pharmaceuticals, Inc. reported revenue of $718.95M. Revenue grew 8.6% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $830.44M.

Key ratios (year ended 2025-12-31)

89.6%
Gross margin (computed)
-8.7%
Operating margin
-5.4%
Net margin
-3.6%
Return on year-end equity
8.6%
Revenue growth (YoY)

Computed by TickerFacts from revenue minus cost of revenue. This may differ from the issuer's reported gross profit or margin; check the revenue and cost definitions.

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-10-22

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30		2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$830.44M$718.95M$661.82M$607.52M$667.24M$579.77M$520.40M$392.75M$408.90M$302.24M$215.00M
Cost of Revenue$99.03M$74.56M$77.91M$83.78M$87.22Mn/a$52.46M$16.66M$15.36M$15.21M$11.99M
Gross Profit (computed)$731.41M$644.39M$583.91M$523.74M$580.02Mn/a$467.94Mn/an/a$287.02M$203.02M
R&D Expense$126.09M$106.23M$108.80M$91.59M$74.55M$90.47M$75.96M$69.10M$89.21M$49.58M$42.79M
Operating Income-$130.46M-$62.28M$81.67M-$5.27M$46.12M$86.03M$173.70M$148.57M$144.44M$99.54M$54.22M
Depreciation & Amortization$101.70M$91.56M$80.41M$84.86M$85.54M$32.59M$18.14M$6.66M$7.06M$8.13M$2.40M
EBITDA-$28.76M$29.28M$162.08M$79.59M$131.67M$118.62M$191.84M$155.23M$151.51M$107.67M$56.62M
Net Income-$109.89M-$38.55M$73.86M$1.32M$60.71M$53.42M$126.95M$113.06M$110.99M$57.28M$91.22M
EPS (Diluted)n/a-$0.68$1.32$0.02$1.04$0.98$2.36$2.10$2.05$1.08$1.76
Total Assets$1.43B$1.45B$1.37B$1.28B$1.70B$1.69B$1.50B$1.16B$977.81M$424.46M$309.57M
Total Liabilities$396.88M$390.93M$332.34M$356.16M$816.30M$873.30M$759.24M$564.85M$524.79M$156.98M$117.81M
Shareholders' Equity$1.03B$1.06B$1.04B$921.52M$886.20M$815.85M$744.86M$595.43M$453.02M$267.48M$191.75M
Cash & Equivalents$179.95M$128.45M$69.33M$75.05M$93.12M$203.43M$288.64M$181.38M$192.25M$100.30M$66.40M
Operating Cash Flow$19.91M$47.33M$171.95M$111.08M$116.83M$127.13M$138.40M$143.13M$128.99M$114.64M$66.81M
Capital Expenditures$1.12M$1.34M$725.0K$551.0K$412.0Kn/a$3.45M$2.74M$844.0K$2.03M$1.60M
Free Cash Flow$18.79M$45.99M$171.23M$110.53M$116.41Mn/a$134.95M$140.39M$128.14M$112.61M$65.21M
Shares Outstanding58.16M57.46M55.74M54.72M53.26M53.26M52.87M52.53M52.32M51.31M49.97M
Weighted Average Diluted Sharesn/a56.45M55.96M55.51M61.68M54.36M53.69M53.82M54.10M53.30M51.71M
EPS (Basic)n/a-$0.68$1.34$0.02$1.13$1.01$2.41$2.16$2.13$1.13$1.84

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView